Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01969669 · ClinicalTrials.gov registry record · Phase 1

A Study to Assess the Effect of Ketoconazole on the Metabolism of ABT-199

A Phase 1 study of Non-Hodgkin's Lymphoma, sponsored by AbbVie.

Completed
Registry status
Phase 1
Development phase
12
Enrollment target
3
Study locations

NCT01969669: Completed Phase 1 study of Non-Hodgkin's Lymphoma, sponsored by AbbVie.

NCT01969669 is a Phase 1 study of Non-Hodgkin's Lymphoma that has completed, run by AbbVie. The registered enrollment target is 12 participants, below the 222-participant average among 63 other Non-Hodgkin's Lymphoma trials with a reported enrollment target (95% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01969669, a Phase 1 study of Non-Hodgkin's Lymphoma, has completed, sponsored by AbbVie.

COMPLETED
Registry status
Phase 1
Development phase
12 participants
Enrollment target
3
Study locations

Study Summary

This is an open-label multicenter, study to assess the pharmacokinetic interaction of ketoconazole with ABT-199 in up to 12 subjects with relapsed or refractory non-Hodgkin's lymphoma.

Primary Outcome

Blood samples for pharmacokinetic (PK) analysis of ABT-199 will be collected at designated timepoints to assess the PK parameters for ABT-199 alone relative to ABT-199 with ketoconazole

Conditions Studied

Interventions

  • DRUG Ketoconazole
  • DRUG ABT-199

Study Locations (3)

Arizona

  • Site Reference ID/Investigator# 97498 - Tucson

New Hampshire

  • Site Reference ID/Investigator# 92593 - Lebanon

New Jersey

  • Site Reference ID/Investigator# 101415 - Hackensack

Trial Details

FieldValue
Enrollment Target 12 participants
Start Date 2013-12
Est. Completion 2014-09
Phase Phase 1
AbbVie

526 total trials

What the finished NCT01969669 record still lists

NCT01969669 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 222-participant average among 63 other Non-Hodgkin's Lymphoma trials with a reported enrollment target (95% lower).

The record links to 1 condition, with Non-Hodgkin's Lymphoma appearing as the primary indexed condition, and to 2 interventions - of which Ketoconazole is the first listed.

NCT01969669 reports a single indexed study location in Arizona, New Hampshire, New Jersey.

Frequently Asked Questions

What is clinical trial NCT01969669 about?

NCT01969669 is a clinical study titled "A Study to Assess the Effect of Ketoconazole on the Metabolism of ABT-199". This is an open-label multicenter, study to assess the pharmacokinetic interaction of ketoconazole with ABT-199 in up to 12 subjects with relapsed or refractory non-Hodgkin's lymphoma.

What is the current status of trial NCT01969669?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2013-12. Estimated completion is 2014-09.

What conditions does trial NCT01969669 study?

This clinical trial studies the following conditions: Non-Hodgkin's Lymphoma.

What interventions are being tested in trial NCT01969669?

The interventions under investigation include: Ketoconazole (DRUG), ABT-199 (DRUG).

Who is sponsoring clinical trial NCT01969669?

This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01969669 being conducted?

This trial has 3 study locations across Arizona, New Hampshire, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Non-Hodgkin's Lymphoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01969669's enrollment target sits among peer trials

12 55th of 63 higher than 7 of 63 other Non-Hodgkin's Lymphoma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Non-Hodgkin's Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02602769 · 12 participants

    Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome

  • NCT02605421 · 12 participants · Phase 2

    Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma

  • NCT02619448 · 12 participants · Early Phase 1

    Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC

  • NCT03311503 · 12 participants · Phase 1

    Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01969669, the US trial registry maintained by the National Library of Medicine. NCT01969669 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.